Höfner

HOF Therapeutics is a biotechnology company focused on developing advanced organ-on-chip models and regenerative therapies using its proprietary Cell Assembly Programmed (CAP) technology. The company specializes in synthesizing functional organ elements, such as full-thickness skin, lung, and vascular models, from stem cells and primary cells to mirror in vivo micro-architecture. These high-fidelity models are utilized for high-throughput drug screening, active ingredient validation, and the study of complex disease phenotypes. HOF Therapeutics aims to set a new standard for preclinical drug development by providing more accurate biological systems for evaluating therapeutic efficacy and safety across various organ systems.